Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose cytarabine plus zanubrutinib for relapsed or refractory primary central nervous system lymphoma
ChiCTR2000039229Phase 2Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine and zanubrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Huashan Hospital. Primary endpoint: Progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
cytarabinezanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2000039229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039229.